Two firms in San Diego County announced partnerships Thursday, one with tech giant IBM and the other with the University of California, Los Angeles.
Edico Genome Corp.
Bioinformatics firm Edico Genome Corp. is partnering with IBM, the company said Thursday, to make Edico's Dragen bio-IT processor available on one of IBM's high-performance computing servers.
Specifically, it has implemented Dragen on the IBM Power Systems S822LC. The server is designed for clients that need large quantities of processing power without a bunch of floor space.
Edico also said that it has implemented an accelerated version of the Broad Institute's Genome Analysis Toolkit on the Dragen processor, reducing the time it takes for analysis tasks.
"Providing Dragen on IBM Power Systems offers both existing IBM customers and additional hospitals and academic centers seeking to build a genomics infrastructure with a rapid, accurate, and easily integrated analysis solution," Edico's CEO Pieter van Rooyen said in a statement.
As part of the collaboration with IBM, Edico has joined the OpenPOWER foundation, a 200-member organization of technology suppliers and users that support and contribute to the Power open architecture. As a member, Edico will be able to access to Power central processing unit processors and systems platforms for optimization, development activities, and advanced hardware technology exploitation.
Edico also has a partnership with Intel Corp. that it inked last year to combine Dragen with Intel processors.
The UCLA Department of Pathology and Laboratory Medicine, and Vista-based Leica Biosystems said Thursday they are in a collaboration concerning digital pathology.
According to the release, UCLA will help validate a digital pathology offering from Leica Biosystems through a team led by Dr. Scott Binder, director of Pathology Clinical Services at UCLA.
Financial details of the deal were not disclosed, nor details of the specifics of the tech involved. The two said that UCLA will provide quantitative feedback on current and next-generation products intended to advance digital pathology in the United States, from bench research to full clinical adoption.
Leica Biosystems is a medical device firm that develops and supplies clinical diagnostics to the pathology market.